Journals / Sağlık Bilimlerinde İleri Araştırmalar Dergisi / 2020 / Cilt: 3 - Sayı: 3

The effect of JAK2V617F Mutation to the Endothelial Cells and the Expression Profiles of SOCS1-4 Genes in Myeloproliferative Neoplasms

Miyeloproliferatif Neoplazilerde JAK2V617F Mutasyonunun Endotel Hücresine Etkisi ve SOCS1-4 Gen Anlatımlarına Yansıması

Pages
135–147
Publication Date
2020-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Future studies will further enlighten the effects of JAK2V617F on EC and its role in thrombotic events.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Patients with myeloproliferative neoplasms (MPN) are at an increased risk of developing thrombosis which leads to significant levels of morbidity and mortality.
📊
Key Findings & Data:Although this propensity for thrombosis has been attributed to increased blood counts, other factors such as endothelial cell (EC) dysfunction likely play an important role.
💡
Conclusion & Impact:Conclusion: Future studies will further enlighten the effects of JAK2V617F on EC and its role in thrombotic events.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Miyeloproliferatif Neoplazi (MPN) · JAK2V617F · Endotel Hücre

Abstract

Objective: Patients with myeloproliferative neoplasms (MPN) are at an increased risk of developing thrombosis which leads to significant levels of morbidity and mortality. Although this propensity for thrombosis has been attributed to increased blood counts, other factors such as endothelial cell (EC) dysfunction likely play an important role. Previous studies have provided evidence of EC involvement by JAK2V617F which is known to be present in blood cells of 50-95% of patients with MPN. Furthermore, the morphological and functional changes of this mutation, a single nucleotide mutation in the cytosolic tyrosine kinase, Janus kinase 2 (JAK2) has not been shown in EC. In addition, the role of epigenetic factors including suppressors of cytokine signaling (SOCS) proteins is also unknown for MPN. In this study, the effects of the JAK2V617F mutation on EC and the SOCS 1-4 genes expression and their methylation profiles were investigated. Materials and Methods: The in vitro transduction method of green fluorescent protein (GFP) labeled lentivirus carrying the JAK2 (wild form) or JAK2V617F mutation into human cord vein endothelial cell (HUVEC) was applied. GFP was determined and analyzed with the flow cytometer. Afterwards, the genetically modified EC population was isolated, gating for GFP signal by cell sorter and then DNA and RNA isolations were performed. Gene expressional changes of SOCS1-4 genes were determined in real time RT-PCR and methylation specific PCR was performed with bisulfite modification of DNA. Results: The successful infection of JAK2, JAK2V617F and GFP vectors into EC were achieved. The comparison of the genetically modified EC revealed no morphological differences. A significant increase in the expressions of SOCS1-4 were detected in mutant EH compared to JAK2 and GFP. It was determined that methylation had no effect on suppression of SOCS1-4 expression detected in GFP and JAK2 EC. Conclusion: Future studies will further enlighten the effects of JAK2V617F on EC and its role in thrombotic events.

Özet

Amaç: Miyeloproliferatif neoplazi (MPN)’li hastalar morbidite ve mortalitesi yüksek tromboz riski taşırlar. Tromboza olan bu yatkınlık, artmış kan hücre sayısı ile bağdaştırılmış olsa da, endotel hücre (EH) fonksiyon bozukluğu gibi faktörler de önemli rol oynamaktadır. EH’nin miyeloproliferatif bozukluklarla olan bağlantısını göstermek üzere yapılan önceki çalışmalarda EH’nin MPN kan hücrelerinde %50-95 oranında mevcut olan JAK2V617F mutasyonunu taşıdığı gösterilmiş, ancak sitozolik tirozin kinaz olan Janus kinase 2 (JAK2) de meydana gelen bu mutasyonun EH üzerinde göstermiş olduğu morfolojik ve fonksiyonel değişiklik gösterilmemiştir. Ayrıca epigenetik faktörlerden Sitokin Sinyal Süpresör (SOCS) proteinleri‘nin MPN’deki etkisi de tam olarak bilinmemektedir. Bu çalışma ile JAK2V617F mutasyonunun EH'de yapmış olduğu etkileri epigenetik açıdan önemli olan, SOCS 1-4 gen anlatımları ve metilasyon durumları incelenmiştir. Gereç ve Yöntem: In vitro yeşil floresan proteini (GFP) ile işaretlenmiş JAK2 (yabanil formu) veya JAK2V617F mutasyonu taşıyan lentivirusün insan kordon veni endotel hücresi (HUVEC) içine transdüksiyon metodu kullanılmıştır. Genetik olarak modifiye edilmiş EH populasyonunda, akımölçer cihazı ile GFP tespit edilmiş ve analizleri yapılmıştır. Ardından hücre ayırıcı ile seçilmiş olan GFP+ hücrelerde DNA ve RNA izolasyonları gerçekleştirilmiştir. SOCS1-4 genlerinin anlatım değerleri gerçek zamanlı RT-PZR tespit edilmiş ve bisülfit modifikasyona maruz bırakılan DNA yardımıyla metilasyona özgü PZR yapılmıştır. Bulgular: JAK2, JAK2V617F ve GFP taşıyan lentiviral vektörlerle başarılı bir şekilde EH enfeksiyonu gerçekleştirilmiştir. Genetiği modifiye edilmiş EH'ler birbirleri ile kıyaslandığında morfolojik bir farklılık saptanmamıştır. SOCS1-4 genlerinde, mutant EH de JAK2 ve GFP'e göre gen anlatım düzeyinde anlamlı artış tespit edilmiştir. GFP ve JAK2 de tespit edilen SOCS1-4 gen anlatım baskılanmasında bu genlerde oluşması muhtemel bir metilasyon olmadığı tespit edilmiştir. Sonuç: Bu konuda gelecekte yapılacak çalışmalar, JAK2V617F’in EH’ler üzerindeki etkilerini ve trombotik olaylarla bağlantılısını açıklamamıza yardımcı olacaktır.

🔖

Cite This Article

GÖKSU, A., HEKİMOĞLU, H., TOKDEMİR, S. S. (2020). The effect of JAK2V617F Mutation to the Endothelial Cells and the Expression Profiles of SOCS1-4 Genes in Myeloproliferative Neoplasms. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, Cilt: 3 - Sayı: 3, 135–147. https://ajindex.com/articles/217146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Levine RL, Wadleigh M, Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4):387-97
  2. James C, Ugo V, Le Couedic JP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434(7037):1144-8
  3. Kralovics R, Passamonti F, Buser AS. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
  4. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33:313-20
  5. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, longterm complication rates, and prognostic factors. Mayo Clin Proc 2006;81(2):159-66
  6. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110(4):1092-7
  7. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991;63:101-6
  8. Craig MK. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Seminars in hematology 2004;41(2 Suppl3):10-4
  9. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005;42(4):239-47
  10. Falanga A, Marchetti M, Evangelista V. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96(13):4261-6
  11. Blann A, Caine G, Bareford D.Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count. Platelets 2004;15(7): 447-9
  12. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thr